Evidence map›Paper›PMID 40400938›Full record

ArticleJournal of thoracic disease2025

A prognostic nomogram based on lymph node skipping metastases in esophageal squamous cell carcinoma.

Wen-Hui Hou, Li Jie, Liao Yao, Yu-Wei Yang, He Fang, Yuan-Yuan Zhao, Xian-Yan Chen, You-Ling Gong, Xiao-Bo Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wen-Hui HouDivision of Thoracic Tumor Multidisciplinary Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Li JieDepartment of Oncology Cancer, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Liao YaoDepartment of Oncology Cancer, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Yu-Wei YangDepartment of Laboratory Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
He FangDepartment of Health Management Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Yuan-Yuan ZhaoDivision of Thoracic Tumor Multidisciplinary Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xian-Yan ChenDivision of Thoracic Tumor Multidisciplinary Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
You-Ling GongDivision of Thoracic Tumor Multidisciplinary Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xiao-Bo DuDepartment of Oncology Cancer, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: At present, the definition of lymph node skipping metastases (NSM) in esophageal squamous cell carcinoma (ESCC) is not uniform, and there were few clinical prognostic models with NSM as a factor. On the other hand, N-staging of ESCC has long been controversial. This study aimed to define NSM in ESCC and investigate its prognostic implications. Meanwhile, according to the cumulative number of cervical, thoracic and abdominal region lymph nodes, a new N-stage was defined and compared with the N-stage of American Joint Committee on Cancer/the Union for International Cancer Control (AJCC/UICC) and Japan Esophageal Society (JES). Methods: ESCC patients who underwent radical esophagectomy with lymph node metastases (LNM) between January 2012 and December 2022 at Mianyang Central Hospital and West China Hospital of Sichuan University. Patients were grouped into training and external validation cohorts. NSM was defined as any LNM outside the primary tumor region. Meanwhile, this study created a new postoperative pathology N-staging [PN(n)] based on the regional division of LNM to compare with the 8th edition of the AJCC/UICC and the 11th edition of JES N-staging. Results: There were 232 patients enrolled (training: 161; validation: 71). Cox-regression identified factors that could predict outcomes independently. Kaplan-Meier survival analysis was performed. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) and calibration plots. Independent risk factors for death included NSM [hazard ratio (HR) =1.5202], age (HR =1.036), T-stage (HR =2.874), and AJCC/UICC N stage (HR =1.9601). Prognostic models for 1-year (AUC: 0.923, 0.985), 3-year (AUC: 0.747, 0.746), and 5-year (AUC: 0.695, 0.713) survival showed high accuracy. Conclusions: NSM is associated with worse overall survival (OS) in ESCC, and the constructed prognostic model effectively predicts OS for ESCC patients.

Indexed as

Esophageal squamous cell carcinoma (ESCC)node skip metastasesnomogramN stageprognostic model

Identifiers

PMID40400938
PMCPMC12093065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.